Impacts of exposure to topical calcineurin inhibitors on metabolism in vitiligo infants

[1]  W. Placek,et al.  The Role of TRM Cells in the Pathogenesis of Vitiligo—A Review of the Current State-Of-The-Art , 2020, International journal of molecular sciences.

[2]  J. Laar,et al.  Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology , 2020, Nature Reviews Rheumatology.

[3]  F. Lin,et al.  Efficacy of the Topical Calcineurin Inhibitors Tacrolimus and Pimecrolimus in the Treatment of Vitiligo in Infants Under 2 Years of Age: A Randomized, Open-Label Pilot Study , 2019, Clinical Drug Investigation.

[4]  Y. Poulin,et al.  Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders , 2019, Journal of cutaneous medicine and surgery.

[5]  R. L. Riding,et al.  The Role of Memory CD8+ T Cells in Vitiligo , 2019, The Journal of Immunology.

[6]  J. Bae,et al.  Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis. , 2019, JAMA dermatology.

[7]  T. Braunberger,et al.  Update on the Management of Vitiligo , 2019, Skin therapy letter.

[8]  Yuan-Pin Hsu,et al.  The effectiveness of topical calcineurin inhibitors comparing with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis. , 2019, Journal of the American Academy of Dermatology.

[9]  H. Nakagawa,et al.  Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits , 2018, The Journal of dermatology.

[10]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[11]  Ronghua Li,et al.  Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta‐analysis , 2017, Photodermatology, photoimmunology & photomedicine.

[12]  L. Kaznacheeva,et al.  The place of diet therapy in the comprehensive treatment of atopic dermatitis in infants , 2017 .

[13]  J. C. Jaworski,et al.  Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis , 2016, BMC Pediatrics.

[14]  S. Chang,et al.  A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter , 2016, Clinical and experimental dermatology.

[15]  E. Wong,et al.  Off-Label Uses of Topical Calcineurin Inhibitors. , 2016, Skin therapy letter.

[16]  J. Bae,et al.  Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: A retrospective study of 159 patients. , 2015, Journal of the American Academy of Dermatology.

[17]  T. Barnetche,et al.  Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. , 2015, Journal of the American Academy of Dermatology.

[18]  D. Margolis,et al.  Association Between Malignancy and Topical Use of Pimecrolimus. , 2015, JAMA dermatology.

[19]  S. Lee,et al.  Functional interpretation of metabolomics data as a new method for predicting long-term side effects: treatment of atopic dermatitis in infants , 2014, Scientific Reports.

[20]  Huang Haiyan,et al.  Effect and mechanism of tacrolimus on melanogenesis on A375 human melanoma cells , 2014, Chinese medical journal.

[21]  W. Carr.  Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations , 2013, Pediatric Drugs.

[22]  Miao-ni Zhou,et al.  CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis , 2012, Molecular medicine reports.

[23]  E. Pope,et al.  A double‐blind, randomized, placebo‐controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo , 2011, The British journal of dermatology.

[24]  K. Rothman,et al.  Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors , 2011, The British journal of dermatology.

[25]  Beppie van den Bogaerde,et al.  Clinical practice , 2011, European Journal of Pediatrics.

[26]  A. Baldo,et al.  Tacrolimus ointment in the management of atopic dermatitis , 2009, Clinical, cosmetic and investigational dermatology.

[27]  M. Picardo,et al.  Clinical practice. Vitiligo. , 2009, The New England journal of medicine.

[28]  A. Xu,et al.  Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo , 2009, International journal of dermatology.

[29]  M J Watts,et al.  Guideline for the diagnosis and management of vitiligo , 2008, The British journal of dermatology.

[30]  F. Schmidt.  Meta-Analysis , 2008 .

[31]  M. Nishimura,et al.  Therapeutic implications of autoimmune vitiligo T cells. , 2006, Autoimmunity reviews.

[32]  A. Paller,et al.  Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[33]  R. English,et al.  Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. , 2005, Veterinary ophthalmology.

[34]  J. Fricain,et al.  Mucosal Pigmentation after Oral Lichen planus Treatment with Topical Tacrolimus , 2005, Dermatology.

[35]  P. Grimes.  New insights and new therapies in vitiligo. , 2005, JAMA.

[36]  S. Dogra,et al.  Topical tacrolimus for treatment of childhood vitiligo in Asians , 2004, Clinical and experimental dermatology.

[37]  T. Tüting,et al.  Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. , 2004, European journal of cell biology.

[38]  G. Ogg,et al.  Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo , 2003, Laboratory Investigation.

[39]  J. Drake,et al.  Lumbar intervertebral disc disease in the pediatric population. , 1992, Pediatric neurosurgery.

[40]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[41]  P. Grimes,et al.  Childhood vitiligo. , 1987, Journal of the American Academy of Dermatology.